PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Company ReportsNippon Shinyaku
Nippon Shinyaku
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
ViltepsoViltolarsen2020-08-122031
Duchenne muscular dystrophy
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Viltolarsen
duchenne muscular dystrophy
,
muscular dystrophies
Aglatimagene besadenovec
lymphoma
,
triple negative breast neoplasms
,
pharmacokinetics
,
healthy volunteers/patients
,
pharmacological phenomena
,
neoplasms
,
breast neoplasms
,
adenocarcinoma
,
neoplasm metastasis
,
carcinoma
,
ovarian neoplasms
,
non-small-cell lung carcinoma
,
pancreatic neoplasms
,
colorectal neoplasms
,
lung neoplasms
,
uterine cervical neoplasms
,
endometrial neoplasms
,
stomach neoplasms
,
urinary bladder neoplasms
,
small cell lung carcinoma
,
biliary tract neoplasms
,
bone neoplasms
,
bone diseases
,
hereditary breast and ovarian cancer syndrome
,
aggression
,
head and neck neoplasms
,
dna repair-deficiency disorders
,
sarcoma
,
ovarian epithelial carcinoma
,
recurrence
,
hypersensitivity
,
gynecomastia
,
prostatic neoplasms
,
castration-resistant prostatic neoplasms
,
heart failure
,
coronary disease
,
coronary artery disease
,
myocardial ischemia
,
heart diseases
,
osteoporosis
,
obesity
,
disease susceptibility
,
hepatocellular carcinoma
,
liver neoplasms
Sodium chloride
healthy volunteers/patients
,
neoplasms
,
heart failure
,
colorectal neoplasms
,
chronic renal insufficiency
,
kidney diseases
,
cystic fibrosis
,
cholangiocarcinoma
,
biliary tract neoplasms
,
gallbladder neoplasms
,
drug-related side effects and adverse reactions
,
renal insufficiency
,
cardiovascular diseases
,
type 2 diabetes mellitus
,
major depressive disorder
,
depressive disorder
,
diabetes mellitus
,
non-small-cell lung carcinoma
,
depression
,
chronic obstructive pulmonary disease
,
obstructive lung diseases
,
sepsis
,
septic shock
,
shock
,
toxemia
,
treatment-resistant depressive disorder
,
lung diseases
,
hidradenitis suppurativa
,
hidradenitis
,
small cell carcinoma
,
obesity
,
fibrosis
,
non-alcoholic fatty liver disease
,
fatty liver
,
hypersensitivity
,
syndrome
,
drug hypersensitivity syndrome
,
carcinoma
,
lung neoplasms
,
hepatocellular carcinoma
,
liver neoplasms
,
small cell lung carcinoma
,
sars-cov-2
,
respiratory tract infections
,
asthma
,
vasculitis
,
churg-strauss syndrome
,
recurrence
,
ovarian neoplasms
,
ovarian epithelial carcinoma
,
gastroesophageal reflux
,
peptic esophagitis
,
esophagitis
,
infections
,
respiratory syncytial virus infections
,
coronavirus infections
,
coronavirus
,
hematologic diseases
,
hypereosinophilic syndrome
,
eosinophilia
,
leukocyte disorders
,
uterine cervical neoplasms
,
covid-19
,
hypertension
,
breast neoplasms
,
postoperative pain
ILGINATINIB
essential thrombocythemia
,
polycythemia vera
,
primary myelofibrosis
,
thrombocytosis
,
polycythemia
Microcrystalline cellulose
carcinoma
,
ovarian neoplasms
,
serous cystadenocarcinoma
,
fallopian tube neoplasms
,
carcinosarcoma
,
hereditary breast and ovarian cancer syndrome
,
mullerian mixed tumor
,
recurrence
,
leukemia
,
myeloid leukemia acute
,
precursor cell lymphoblastic leukemia-lymphoma
,
myeloid leukemia
,
precursor t-cell lymphoblastic leukemia-lymphoma
,
acute disease
,
lymphoid leukemia
NS-018
essential thrombocythemia
,
polycythemia vera
,
primary myelofibrosis
,
thrombocytosis
,
polycythemia
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use